Role of Sotagliflozin in Managing Heart Failure in Diabetes

Ramesh Vineesha Kavadi

doi:10.46956/ijihd.v9i2.623

Kavadi Ramesh Vineesha Priyadarshini Institute of Pharmaceutical Education and Research 5thMile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

DOI https://doi.org/10.46956/ijihd.v9i2.623

Abstract

A chronic illness that impairs heart function is heart failure. This malfunction can put strain on other organs and be especially dangerous for those who have long-term conditions like diabetes and high blood pressure. Patients with diabetes are more likely to develop heart failure. Sotagliflozin is an oral medication used to treat diabetes. A dual sodium drug called sotagliflozin shows promise in the treatment of heart failure. An essential new family of medications for the treatment of diabetes is the sodium-dependent glucose transporter 2 (SGLT2) inhibitors. The goal of developing SGLT2 inhibitors has been to achieve high SGLT2 protein selectivity compared to SGLT1 protein. Treating diabetes with a single drug that combines the inhibition of SGLT1 and SGLT2 would offer complementing insulin-independent strategies. Thus, sotagliflozin (LX4211) was created as a dual SGLT1 and SGLT2 inhibitor. Large postprandial glucose decrease, increase of glucagon-like peptide 1, and mild urine glucose excretion are the distinguishing clinical aspects of dual inhibitor of SGLT1 and SGLT2. These characteristics might have an impact on how sotagliflozin is used clinically to treat diabetes.

Keywords: Sotagliflozin (LX4211), SGLT1 and SGLT2 inhibitors, pharmacokinetics, pharmacodynamics

Downloads

Download data is not yet available.

References

1. Nagoshi T, Yoshimura M, MC Rosano G, D Lopaschuk G, Mochizuki S. Optimization of cardiac metabolism in heart failure. Current pharmaceutical design. 2011 Dec 1;17(35):3846-53. https://doi.org/10.2174/138161211798357773.
2. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. The American journal of cardiology. 2006 Sep 4;98(5):14-8. https://pubmed.ncbi.nlm.nih.gov/16931201/
3. Kolapudi RK, Kapudasi J, Koppula SB, Chandu B. Stem Cells Treatment for the Future Heart Diseases. Drug Invention Today. 2012 Jun 1;4(6).
4. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiological reviews. 2011Apr;91(2):733-94. http://doi.org/10.1186/s12933-019-0828-
5. Li Y, Shi Z, Chen L, Zheng S, Li S, Xu B, Liu Z, Liu J, Deng C, Ye F. Discovery of a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor (HSK0935) for the treatment of type 2 diabetes. Journal of Medicinal Chemistry. 2017 May 25;60(10):4173-84.http://doi.org/10.1186/s12933-019-0828-
6. Chu KF, Song JS, Chen CT, Yeh TK, Hsieh TC, Huang CY, Wang MH, Wu SH, Yao CH, Chao YS, Lee JC. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors. Bioorganic chemistry. 2019 Mar 1;83:520-5.
7. Yuan MC, Yeh TK, Chen CT, Song JS, Huang YC, Hsieh TC, Huang CY, Huang YL, Wang MH, Wu SH, Yao CH. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2. European Journal of Medicinal Chemistry. 2018 Jan 1;143:611-20.
8. Ng WL. Synthetic Studies towards Carbocyclic Analogues of SGLT2 Inhibitors. The Chinese University of Hong Kong (Hong Kong); 2014.
9. Mezza T, Muscogiuri G, Sorice GP, Clemente G, Hu J, Pontecorvi A, Holst JJ, Giaccari A, Kulkarni RN. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes. 2014 Mar 1;63(3):994-1007. http://doi.org/10.1186/s12933-019-0828-
10. Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A. Improved glycemic control in mice lacking Sglt1 and Sglt2. American Journal of Physiology-Endocrinology and Metabolism. 2013 Jan 15;304(2):E117-30.
http://www.accessdata.fda.gov/drugsatfda_
11. Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diabetes and Vascular Disease Research. 2015 Mar;12(2):101-10. http://www.accessdata.fda.gov/drugsatfda_
12. Patel K, Carbone A. Sodium-glucose cotransporters as potential therapeutic targets in patients with type 1 diabetes mellitus: an update on phase 3 clinical trial data. Annals of Pharmacotherapy. 2019 Dec;53(12):1227-37.
13. Long A, Salvo M. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure. Annals of Pharmacotherapy. 2023 Nov 28:10600280231211179.
14. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes and Vascular Disease Research. 2015 Mar;12(2):78-89.